We are proud to announce that our flagship technology, Exashape, has officially entered the Swedish market through an exclusive distribution partnership with Apgar. This move marks a significant milestone in our mission to bring advanced regenerative solutions to surgeons and patients across the Nordics.
Scandinavia has long been a global leader in oncological care, supported by robust data tracking such as the Swedish National Quality Registry for Breast Cancer (NKBC) [1] and the NORDCAN database [2]. With approximately 8,000 to 10,000 new breast cancer diagnoses annually in Sweden [3] and nearly 5,000 in Denmark [2], the demand for reconstructive solutions that prioritize both surgical efficiency and long-term aesthetic outcomes has never been higher across the region.
ExaShape, our acellular bovine pericardium matrix (ABPM), is designed to integrate seamlessly into modern surgical workflows, particularly as European and Nordic centers continue to lead the shift toward pre-pectoral reconstruction [4].
By facilitating a reliable pre-pectoral approach, ExaShape eliminates the need for pectoralis major detachment, effectively resolving animation deformity while optimizing surgical workflow.
Flavio Nanni, COO & Founder “I truly see our entry into Denmark and Sweden as an opportunity to expand the ExaShape user community and to penetrate a competitive and highly selective market. This will encourage further collaboration between clinicians and open up opportunities for additional improvements. It is also beneficial for patients, who will be able to take advantage – just like women living in the countries where we are already present – from innovative and highly efficient technology tailored to their needs as cancer patients (i.e. those who are very ‘vulnerable’). For doctors in those countries, it represents a state-of-the-art therapeutic tool that is proving so effective that it has already become the ‘gold standard’ in many nations.”
Silvia Segales Santolaria Exashape Business Development Manager: “I’m very happy to see ExaShape entering Denmark and Sweden, a meaningful step towards supporting more surgeons and improving patient outcomes in breast reconstruction”
We look forward to collaborating with our distributor to redefine what is possible in regenerative surgery.
Stay tuned as we bring this partnership to life in May, working side-by-side with local surgeons in the OR for the inaugural ExaShape cases in the Nordics.
References & Clinical Context
[1] Swedish Regional Cancer Centres (RCC). National Quality Registry for Breast Cancer (NKBC). Annual Reports on diagnostics, treatments, and long-term reconstructive outcomes.
[2] Association of Nordic Cancer Registries / IARC. NORDCAN Database. Denmark Fact Sheet (Breast Cancer Incidence).
[3] Löfgren, L., et al. “Validation of data quality in the Swedish National Register for Breast Cancer.” BMC Public Health (2019).
[4] [3] Casella, D., et al. “Dual-Plane Retro-pectoral Versus Pre-pectoral DTI Breast Reconstruction: An Italian Multicenter Experience” Aesthetic Plastic Surgery (2021).
Important information This article is general education, not medical advice. Tap to read the full medical, regulatory & legal notice.
This article is provided by Advanced Biomedical Concept for general informational and educational purposes only. It does not constitute medical, surgical, diagnostic, or other professional healthcare advice, and it is not a substitute for consultation with a suitably qualified healthcare professional. Reading it creates no doctor–patient or other professional relationship. Nothing here should be used to diagnose, treat, cure, or prevent any disease or condition, or to make decisions about medical care. Always seek the advice of a physician or other qualified provider with any questions about a medical condition or treatment, and never disregard or delay professional advice because of something you have read here.
Any reference to Advanced Biomedical Concept products (including ExaShape and ExaFat) is provided for general information only. These are medical devices intended to be used by appropriately trained healthcare professionals strictly in accordance with their applicable, current Instructions for Use (IFU). Regulatory status (including CE marking and classification under the EU Medical Device Regulation), market availability, and approved indications differ between countries and may change over time; a device referred to here may not be available or approved in your country. This content is not intended as, and must not be relied upon as, a statement or claim of safety, clinical performance, or efficacy beyond what is set out in the applicable IFU and current regulatory approvals. Product-specific information is directed at healthcare professionals and is not intended to promote, advertise, or offer any medical device to the general public where such promotion is restricted or prohibited by law.
Statements reflect information believed to be accurate at the date of publication and may be updated or corrected without notice. Any statements regarding the future are expectations or general views, not guarantees. Clinical outcomes depend on many individual factors, results vary from person to person, and no particular result is promised or implied. Where third-party studies, sources, or external links are referenced, they are provided for convenience and information only and do not imply endorsement, and Advanced Biomedical Concept is not responsible for their content.
To the fullest extent permitted by applicable law, Advanced Biomedical Concept and its officers, employees, contributors, and representatives (each acting in that capacity and on behalf of Advanced Biomedical Concept) accept no liability for any loss, injury, or damage of any kind arising directly or indirectly from use of, or reliance on, this content. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.
Questions about this material can be directed to us via our contact page.
Last reviewed: June 16, 2026.
